Focusing on targeting the 3 foundational pathways in PAH is an effective treatment strategy with clinical benefits2
Not all prostacyclin pathway agents are the same.1 UPTRAVI® selectively targets the IP receptor—the only established relaxant prostanoid receptor in the human pulmonary artery6,7
Three established prostanoid receptors in the human pulmonary artery7
Prostanoid receptors in other systems throughout the body
There are 2 categories of prostanoid receptors in vascular cells1:
Vasodilative
Vasoconstrictive
Selexipag and its active metabolite are selective for the IP receptor vs other prostanoid receptors (EP1-4, DP, FP, and TP)6†
The clinical significance of this mechanism is unknown
Prostanoid receptors are located on various tissue types throughout the body1,8
Peripheral systemic artery
Gastrointestinal tract
Nerve cells
